
Keywords: 5-FU; 5-fluorouracil; CEA; carcinoembryonic antigen; CYP3A4; cytochrome 3A4; DPD; dihydropyrimidine dehydrogenase; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; EMA; European Medicines Agency; FDA; Food and Drug Adminis